) --




) hit a new 52-week high Friday as it traded at $88.14 compared with its previous 52-Week high of $87.64. Shire is changing hands at $87.80 with 118,797 shares traded as of 9:37 a.m. ET. Average volume has been 431,200 shares over the past 30 days.

Shire has a market cap of $15.7 billion and is part of the

health care

sector and


industry. Shares are up 19.2% year to date as of the close of trading on Thursday.

Shire plc, together with subsidiaries, engages in the research, development, manufacture, sale, and distribution of pharmaceutical products. The company operates through two segments: Specialty Pharmaceuticals and Human Genetic Therapies. The company has a P/E ratio of 26.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 15.6.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full

Shire Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center